Dynacure to Present Preclinical Data on Disease Progression Modelling and ASO-Mediated Dynamin 2 Knockdown at World Muscle Society (WMS) MeetingMichael Jaramillo2021-09-16T06:49:48-07:00September 16, 2021|
Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear MyopathiesMichael Jaramillo2021-06-09T00:00:00-07:00June 8, 2021|
Dynacure Recognizes Rare Disease Day 2021Michael Jaramillo2021-02-26T00:08:58-08:00February 26, 2021|
Dynacure Announces Issuance of U.S. Patent for DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)Michael Jaramillo2021-01-25T23:27:41-08:00January 25, 2021|
Dynacure Announces Appointment of Jean M. Franchi to its Board of DirectorsMichael Jaramillo2021-01-20T15:27:23-08:00January 20, 2021|
Dynacure announces publication of Hierarchical Bayesian modelling of disease progression in Orphanet Journal of Rare DiseasesMichael Jaramillo2021-01-15T05:01:44-08:00January 15, 2021|
Dynacure Announces New Program, DYN201, for Hereditary Spastic Paraplegia (HSP), a Rare Neurodegenerative Diseasesiteadmin2020-11-07T00:40:58-08:00October 13, 2020|
Dynacure to Present Disease Progression Model and Natural History Study Data at the 25th Annual Congress of the World Muscle Society (WMS25)siteadmin2020-11-07T02:09:54-08:00September 28, 2020|
Dynacure Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for DYN101 for Myotubular and Centronuclear Myopathies (CNM)siteadmin2020-11-07T02:12:27-08:00July 30, 2020|
Dynacure Announces Presentations at Upcoming Investor Conferencessiteadmin2020-11-07T02:13:48-08:00July 28, 2020|
Community